An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Advanced Solid TumorHematological Malignancy

Interventions

DRUG

YY201

Oral administration under fasting state.

Trial Locations (1)

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Yuyao Biotech Co., Ltd.

INDUSTRY